FDG-PET-CT for staging of high-risk breast cancer patients reduces the number of further examinations: A pilot study

References

• Pestalozzi B, Castiglione M, on behalf of the ESMO guidelines working group. Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19(Suppl 2):ii7–ii10.
   PubMed Web of Science ®Google Scholar
• Hoeven van der JJM, Krak NC, Hoekstra OS, Comans EF, Boom RP, van Geldere D, . 18F-2-Fluoro-2-Deoxy-D-Glucose positron emission tomography in staging of locally advanced breast cancer. J Clin Oncol 2004;22:1253–9.
   PubMed Web of Science ®Google Scholar
• Oost van FJ, Hoeven van der JJM, Hoekstra OS, Voogd AC, Coebergh JW, van de Poll-Franse LV. Staging in patients with locoregionally recurrent breast cancer: Current practice and prospects for positron emission tomography. Eur J Cancer 2004;40:1545–53.
   PubMed Web of Science ®Google Scholar
• Port ES, Yeung H, Gonen M, Liberman L, Caravelli J, Borgen P, . FDG-PET scanning affects surgical management in selected patients with high-risk operable breast carcinoma. Ann Surg Oncol 2006;13:677–84.
   PubMed Web of Science ®Google Scholar
• Mahner S, Schirmacher S, Brenner W, Jenicke L, Habermann CR, Avril N, . Comparison between FDG-PET, conventional imaging and computed tomography for staging of breast cancer. Ann Oncol 2008;19:1249–54.
   PubMed Web of Science ®Google Scholar
• Eubank WB, Mankoff DA, Takasugi J, Vesselle H, Eary JF, Shanley TJ, . 18Flurorodeoxyglucose positron emission tomography to detect mediastinal mammary or internal mammary metastases in breast cancer. J Clin Oncol 2001;19:3516–23.
   PubMed Web of Science ®Google Scholar
• Danforth DN, Aloj L, Carrasquillo JA, Bacharach SL. Chow C, Zujewski J, . The role of 18F-FDG-PET in the local-regional evaluation of women with breast cancer. Breast Cancer Res Treat 2002;75:135–46.
   PubMed Web of Science ®Google Scholar
• Dizendorf EV, Baumert BB, Schulthess von GK, Lütolf UM, Steinert HC. Impact of whole-body 18F-FDG PET on staging and managing patients for radiation therapy. J Nucl Med 2003;44:24–9.
   PubMed Web of Science ®Google Scholar
• Groheux D, Moretti J-L, Baillet G, Espie M, Giacchetti S, Hindie E, . Effect of 18F-FDG PET-CT imaging in patients with clinical stage II and III breast cancer. Int J Radiat Oncol Biol Phys 2008;71:1–10.
   Web of Science ®Google Scholar
• Fuster D, Duch J, Paredes P, Velasco M, Muñoz M, Santamaría G, . Preoperative staging of large primary breast cancer with [18F]Fluorodeoxyglucose positron emission tomography-computed tomography compared with conventional imaging procedures. J Clin Oncol 2008;26:4746–51.
   PubMed Web of Science ®Google Scholar
• Dose J, Bleckmann C, Bachmann S, Velasco M, Muñoz M, Santamaría G, . Comparison of FDG-PET and “conventional diagnostic procedures” for the detection of distant metastases in breast cancer patients. Nucl Med Comm 2002;23:857–64.
   PubMed Web of Science ®Google Scholar
• Isasi CR, Moadel RM, Blaufox MD. A meta-analysis of FDG-PET for the evaluation of breast recurrence and metastases. Breast Cancer Res Treat 2005;90:105–12.
   PubMed Web of Science ®Google Scholar
• Eubank WB, Mankoff D, Bhattacharya M, Gralow J, Linden H, Ellis G, . Impact of FDG-PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer. Am J Rontgenol 2004;183:479–86.
   PubMed Web of Science ®Google Scholar
• Gerber B, Seitz E, Muller H, Krause A, Reimer T, Kundt G, . Peri-operative screening for metastatic disease is not indicated in patients with primary breast cancer and no clinical signs of tumor spread. Breast Cancer Res Treat 2003;82:29–37.
   PubMed Web of Science ®Google Scholar
• Cermik TF, Mavi A, Basu S, Alavi A. Impact of FDG-PET on pre-operative staging of newly diagnosed breast cancer. Eur J Nucl Med Mol Imaging 2008;35:475–83.
   PubMed Web of Science ®Google Scholar
• Bellon JR, Livingston RB, Eubank WB, Gralow JR, Ellis GK, Dunnwald LK, . Evaluation of the internal mammary nodes by FDG-PET in locally advanced breast cancer. Am J Clin Oncol 2004;27:407–10.
   PubMed Web of Science ®Google Scholar
• Shie P, Cardareli R, Brandon D, Erdman W, Abdulrahim N. Meta-analysis: Comparison of FDG-PET and bone scintigraphy in the detection of bone metastases in patients with breast cancer. Clin Nucl Med 2008;33:97–101.
   PubMed Web of Science ®Google Scholar
• Dietrich CF, Kratzer W, Strobe D, Danse E, Fessl R, Bunk A, . Assessment of metastatic liver disease in patients with extrahepatic tumors by contrast-enhanced sonography versus CT and MRI. World J Gastroenterol 2006;12:1699–705.
   PubMed Web of Science ®Google Scholar
• Klaeser B, Wiederkehr O, Koeberle D, Mueller A, Bubeck B, Thuerlimann B. Therapeutic impact of FDG-PET in the pre-and post-operative staging of patients with clinically intermediate or high-risk breast cancer. Ann Oncol 2007;18:1329–34.
   PubMed Web of Science ®Google Scholar
• Tran A, Pio BS, Khatibi B, Czernin J, Phelps ME, Silverman DHS. FDG PET for staging breast cancer in patients with inner-quadrant versus outer-quadrant tumors. Comparison with longterm clinical outcome. J Nucl Med 2005;46:1455–9.
   PubMed Web of Science ®Google Scholar